Declining value of alanine aminotransferase in screening of blood donors to prevent posttransfusion hepatitis B and C virus infection. The Retrovirus Epidemiology Donor Study.
about
Measuring the value of public health systems: the disconnect between health economists and public health practitionersHigh levels of subgenomic HCV plasma RNA in immunosilent infectionsCost-effectiveness of blood donor screening for Babesia microti in endemic regions of the United States.Prevalence and associations of hepatitis C viremia in hemodialysis patients at a tertiary care hospitalDoes the Strategy of Risk Group Testing for Hepatitis C Hit the Target?Optimal blood donation screening annotation.Current viral risks of blood and blood products.Routine serologic testing for hepatitis C virus infection should be instituted among dialysis patients.Pharmaco-economics of blood transfusion safety: review of the available evidence.US NAT yield: where are we after 2 years?Incidence and estimated rates of residual risk for HIV, hepatitis C, hepatitis B and human T-cell lymphotropic viruses in blood donors in Canada, 1990-2000.The National Heart, Lung, and Blood Institute retrovirus epidemiology donor studies (Retrovirus Epidemiology Donor Study and Retrovirus Epidemiology Donor Study-II): twenty years of research to advance blood product safety and availability.Nucleic acid testing: Is it the only answer for safe Blood in India?A case-control study of factors associated with resolution of hepatitis C viremia in former blood donors (CME)Current testing strategies for hepatitis C virus infection in blood donors and the way forwardEfficacy of a hepatitis C virus core antigen enzyme-linked immunosorbent assay for the identification of 'window-phase' blood donations.High false-negative rate of anti-HCV among Egyptian patients on regular hemodialysis.Development of a simple and highly sensitive enzyme immunoassay for hepatitis C virus core antigen.Estimated risk of transfusion-transmitted viral infections in Spain.A model of the health and economic impact of posttransfusion hepatitis C: application to cost-effectiveness analysis of further expansion of HCV screening protocols.Clinical evaluation of an HIV-1 and HCV assay and demonstration of significant reduction of the HCV detection window before seroconversion.Detection of hepatitis C core antigen in the antibody negative 'window' phase of hepatitis C infection.Efficacy of HCV core antigen detection during the preseroconversion period.Antibodies to a novel antigen in acute hepatitis C virus infections.Detection of HCV core antigen in human serum and plasma with an automated chemiluminescent immunoassay.Detection of a healthy carrier of HCV with no evidence of antibodies for over four years.The value of increased neopterin levels in reducing transfusion-transmitted virus infections: detection of a donation from a HBsAg positive chronic carrier by screening of neopterin in Turkish blood donors.Seroprevalence of known and putative hepatitis markers in United States blood donors with ALT levels at least 120 IU per L.Good evidence begets good policy: or so it should be.Long-term survival in transfusion recipients in Sweden, 1993.Cost-effectiveness of nucleic acid test screening of volunteer blood donations for hepatitis B, hepatitis C and human immunodeficiency virus in the United States.Impact of HCV 3.0 EIA relative to HCV 2.0 EIA on blood-donor screening.Current risks of viral hepatitis from blood transfusions.De novo HCV infection among dialysis patients: a prospective study by HCV core antigen ELISA assay.Transfusion-transmitted viral infections: building bridges to transfusion medicine to reduce risks and understand epidemiology and pathogenesis.Four-year survival of transfusion recipients identified by hepatitis C lookback.Performance of ORTHO HCV core antigen and trak-C assays for detection of viraemia in pre-seroconversion plasma and whole blood donors.Prevention of transfusion-transmitted hepatitis E by donor-initiated self exclusion.Prevalence and incidence of hepatitis C in injecting drug users attending genitourinary medicine clinics.Hepatitis B Virus Blood Screening: Need for Reappraisal of Blood Safety Measures?
P2860
Q24657827-ED72984A-35E9-480C-A7C8-64CB582D0652Q27481224-443C6883-642E-47D0-A0B3-9B995D6DE912Q33688664-6D4E266B-2B00-4DB9-9078-4A392F8D830AQ33762749-8123E4DF-8945-4AC4-AB20-61C6E7DDC5EAQ33858322-11D12180-041A-4214-A86A-E3027193E2BFQ33992800-E76F57CE-58C5-4D48-A9ED-2185FAC06C6EQ34087426-85F2794E-BD89-45AD-9DF8-D1B777F1FB5FQ34113837-D688DA29-ED79-43B6-9BA9-4EEC1B808A0DQ34803014-BA9C8366-18EF-49C9-82DE-D9091CF3171BQ34830197-5E0003E3-2ABC-4C40-9825-D259EF93FFD8Q36078723-B4AA28E2-2F5D-4E55-BF92-354D83DF8938Q36252455-65544072-0E90-4673-9385-CA41A6A6A8A2Q36662780-D36D7186-8838-4403-89A4-AC99EECA5EA7Q36863802-7BB55184-C3F7-4ECE-8D74-806ABE6A2CD7Q38198619-F1FC00E4-5179-4E40-B1CA-57EAB7F77612Q38461450-1E39BB0E-BC86-4C9F-9567-9CE6A6ADC5EFQ38989981-035F46ED-5734-4CCB-9728-3BE40B3B8300Q39449520-71BA5BA6-7206-45B9-8240-76E2D6F47D18Q40626774-4B29E1DB-B6F9-4FBA-875E-FFDDF0B16250Q40741047-3317F233-5F00-45E8-91B1-C5A6900D8BA5Q42982079-A1414332-88BB-4F5E-A6C5-A65214BABFC0Q42998259-6641495F-4D2C-4E00-BD02-ABAE240B5277Q43000848-71C6BC8D-463E-439F-9819-54266F828253Q43034612-297CD4F9-BD6B-4CF0-8840-3080DC8532F5Q43037481-DF1B1B0B-C613-462C-BF61-557A14E03AFBQ43047994-A2023F0D-7BBA-4289-BFCD-A5DB78AF32A3Q43557676-BD569274-262E-4E69-A5D2-83CC33773990Q43635344-55FF3208-3942-4988-A61D-343E91949B4CQ44083868-E632C275-A436-4329-BDD5-84F2BD48C6FFQ44681875-AF6B9C36-9A46-40D9-8CEF-6AE76345C939Q45672786-27B0EC2B-6004-4449-A204-5075B0BE3C70Q46126583-B2910B1E-E14B-4183-B8E6-D2681CB315A4Q46150062-021DAD53-D285-491F-B86F-B179A1555441Q46414212-DB36AD8B-CA8E-4F24-A816-7A1CC00DCA6CQ46854672-E423067F-D718-4E23-97D0-80C25EF0F38AQ50110000-5994B1BF-08AD-4CD9-9E8F-682F583D58D4Q50750366-2ECAA559-4B99-4536-8AEC-749D60584EDAQ50767714-AF1F0FE9-306D-45E4-A442-379BCAD3DEF3Q51126531-9CA64522-119B-4BF2-AF02-8B3DBB40504FQ51743195-920560FB-6BEA-4574-8F74-D296824779A2
P2860
Declining value of alanine aminotransferase in screening of blood donors to prevent posttransfusion hepatitis B and C virus infection. The Retrovirus Epidemiology Donor Study.
description
1995 nî lūn-bûn
@nan
1995年の論文
@ja
1995年学术文章
@wuu
1995年学术文章
@zh
1995年学术文章
@zh-cn
1995年学术文章
@zh-hans
1995年学术文章
@zh-my
1995年学术文章
@zh-sg
1995年學術文章
@yue
1995年學術文章
@zh-hant
name
Declining value of alanine ami ...... irus Epidemiology Donor Study.
@en
Declining value of alanine ami ...... irus Epidemiology Donor Study.
@nl
type
label
Declining value of alanine ami ...... irus Epidemiology Donor Study.
@en
Declining value of alanine ami ...... irus Epidemiology Donor Study.
@nl
prefLabel
Declining value of alanine ami ...... irus Epidemiology Donor Study.
@en
Declining value of alanine ami ...... irus Epidemiology Donor Study.
@nl
P2093
P1433
P1476
Declining value of alanine ami ...... irus Epidemiology Donor Study.
@en
P2093
AuBuchon JP
Kleinman SH
Korelitz JJ
Schreiber GB
P304
P356
10.1046/J.1537-2995.1995.351196110893.X
P577
1995-11-01T00:00:00Z